Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
False. I believe that will be the initial perception but I don't believe it will remain true for long. If I thought MDT was going to walk away and neither they or another big company would step in very quickly, I would not have told my wife to write $3 on the February calendar.
Message in reply to:
You said:
“ I think we will get a very small bump due to the $11M payment and payoff of the loan which frees us from Medtronic oversight. But it also "frees" us from the Medtronic relationship, so I am predicting a fairly significant dip in price shortly after, as this realization sets in and the anti-Titan-ers declare victory via premature obituaries for Titan Medical as a company. “
You obviously think the Medtronic relationship is over after the final milestone.
For the record Geo, I agree with you about milestone 4. I think we will get a very small bump due to the $11M payment and payoff of the loan which frees us from Medtronic oversight. But it also "frees" us from the Medtronic relationship, so I am predicting a fairly significant dip in price shortly after, as this realization sets in and the anti-Titan-ers declare victory via premature obituaries for Titan Medical as a company. That being said, and based on things I heard and saw including four very experienced robotic surgeons happily testing Enos in the lab, I told my wife to mark the calendar with my prediction of greater than $3 by end of February. Just my best guess at the moment.
I have no reason to believe anything was misrepresented by this new team, as much of what they said was subsequently shown to us in the lab and proven true.
I was never a Randall fan, and I needed confirmation of certain things before passing judgment on Mr. McNally. I now think he contributed well to the advancement of the Enos system but when his focus turned more toward funding and some questionable content in his presentations, I agree it was time for a change but I remain thankful for his earlier contributions.
Message in reply to:
Which is why I do not reach out to Titan people anymore. Stephen Randall was a flat-out bull-shytter, and, of course, he is gone with all the rest of’em. I clearly understand the state of things as they are right now. They are dire as I see it. But there are still many unanswered questions. Again, it does not make sense to me that Titan went all out on expansion just a short time ago. Perhaps that is one of the main reasons why McNally was relieved of his duties. He seems to be proficient at making one bad decision after another. And none of us know what was redacted in the MDT agreement. Lots of assumptions but no one truly knows. I do give Mustang credit for actively seeking knowledge. I think he has always been a bit overly optimistic but he does do his homework and he is pro-active. History has shown us over and over that the management of this company lacks transparency - or else they are just extremely incompetent. I believe they purposely mislead. I highly doubt Milestone 4 moves the needle on this much, if at all. It really comes down to what Medtronic is going to do. Most here agree, if the agreement is not extended or an equity stake is not taken, this thing will crash and burn. I am mentally preparing myself for that to happen.
Geo, go with your gut on this one. It obviously means Titan isn't going 6 feet under. But by all means, I still recommend you reach out to them with any questions! They are surprisingly forthcoming on some matters. You just need to ask the right questions.
Message in reply to:
If Titan is about ready to be buried 6 feet under, one of the things I am really trying to understand is WHY the recent expansion and job openings in the Research Triangle?
Those are three new patent applications, not approved patents, to be clear. For technology developed under Mr. McNally's watch. But I guess that proves he was completely useless, right?
continuity, your message footer says "All posts IMHO", but this one must be more than just an opinion - Too many of us agree, so I'm ready to call it fact!
Message in reply to:
FDA sucks! EOM.
__________________
All posts are IMHO!
Canada is now recognizing Covaxin for travel across the border. Now that it has their attention, they need Canadian EUA so Ocugen can start selling it!
With any luck, deployment of Covaxin in Canada will show good results quickly and push the FDA into EAU approval as well!
Funny you should mention this. I just asked Mr. McNally yesterday if they sought independent valuation from the likes of J P Morgan or Duffy and Phelps, as examples. My suggestion was that the info could be shared publicly to show shareholders just how undervalued TMDI really is, so some folks with the financial means could apply a larger SCOOP.
From another place where useful information is shared and nobody has to worry needlessly about false information for very long because a correction is sure to follow quickly:
"In consideration for Matrix providing the exclusive rights under its patent rights and related know-how relating to Tempol within the licensed fields..."
Exclusive.
Here's more:
"The license includes the worldwide use of Tempol for the treatment of all respiratory diseases including asthma, respiratory syncytial virus, influenza and COVID-19."
Matrix Biomed owned the rights, and licensed them to Adamis. 18 months ago, by the way...
https://www.globenewswire.com/en/news-release/2020/06/15/2048114/32832/en/Adamis-Pharmaceuticals-Announces-License-to-Commercialize-Tempol-a-Novel-Investigational-Anti-inflammatory-and-Antioxidant-Drug-for-the-Treatment-of-Respiratory-Diseases-Including-.html
pmontx, not sure what to tell you...
Definitely a punch in the gut this morning. I haven't been following my own advice lately and badgering them for info; some of that is on me as for my own emotional response to today's news. So I haven't been seeking that "transparency" by actively pursuing it. Yes, it sucks. Was I lied to? I don't think so; I think it was the most accurate information they had at the time. Program Management can only be so accurate when projecting timelines for a project as complex as a surgical robotic system, especially if other factors arise that could not possibly have been foreseen. You create a plan, you march to it, and at any fork in the road they have to make a choice as to what they believe is best for the overall program. It would be unfair of me to say I think they did the wrong thing because I don't know what the alternatives would be. March forward with a system that probably wouldn't get FDA clearance? That would have been a much more devastating way to end 2022 or enter 2023. However...
4 millions shares have been BOUGHT so far today. Great price, too. Bottomed out at what, 99 cents pre-market? We've regained about half of that loss in 2 hours of market being open. I don't expect to close over $1.50 but the trend for the day isn't so bad, given our opening price.
JnJ recently announced a TWO year delay for Ottava. Could it have been worse for Titan? Obviously. But it wasn't.
When I first read the news this morning, my initial thought was "How fast can I get out of this stock, before PPS tanks completely?" But I decided to wait and see what the real story is. And this is my take:
The two biggest factors for me are first and foremost, the IP portfolio, and once MDT came into the picture, that was second. IP hasn't changed, except another 2 patents approved on Tuesday and the count continues to rise - an ongoing positive for the company despite their unwillingness to tout it publicly to the extent that I would. Then there's Medtronic... A few pieces I'm tying together...
Milestone 4 still on track for end of year per the CC today. And the revenue that represents.
Mr. McNally commented on the shared values and vision for robotic surgery - inherently a very forward looking statement.
He then proceeds to answer the question about the future with Medtronic by saying it would be inappropriate to comment on that right now. If there was nothing forthcoming, it would be ENTIRELY appropriate to comment on it today, especially since they already set us up for a PPS bloodbath. It's only inappropriate to comment on it if there is SOMETHING to comment on.
He mentioned the segregation of development of Enos from the co-development project for MDT. So if that contract work was to go away completely upon conclusion of Milestone 4, they would be looking to downsize. Instead, they recently announced the expansion of their footprint at Chapel Hill. This is not the action of a company that is about to lose one of their two primary programs.
So I will continue to hold all my shares (never sold one yet) with my fingers crossed that by the end of the year, there will be news that will move the needle beyond yesterday's closing price, and hopefully a double from there. And I do recognize there is a little blind faith involved, and a little of me just being stubborn, but also a bit of evidence as I see it. As well as whoever the folks are who are buying over four million shares so far today.
Message in reply to:
Hey Mustang, not to put you on the spot, but were you lied to back in April when you mentioned how transparent Titan management was with moving forward .. What the heck happened with that baloney?
posilock, where ya been???
Great Link, continuity...
Folks should look at India's rates vs. U.S. and remember that India has 3 times as many people as USA. This shows that the U.S. infection RATE is almost TWENTY TIMES that of India, which is Covaxin's home country.
Message in reply to:
They are already available! They are in India and people have been using this vaccine there. The people of India needed WHO to approve the vaccine so they could leave the country and enter other countries where a requirement is that you are vaccinated.
India is doing great!
https://www.google.com/search?q=india+covid+cases&oq=india+covid+cases&aqs=edge..69i57j0i433i457i512j0i512l6.6739j0j1&sourceid=chrome&ie=UTF-8
They have a better record than countries using mRNA vaccines!
Another thought on Mr. Zaring and the timing of his Titan tenure...
which was July 2019 to Feb 2020.
We know the details were pretty much determined before the April 2020 MDT money came in. Beginning of June, the big deal was announced; had to be in the works while Mr. Zaring was there. Would MDT not rely on his knowledge and expertise in not only surgical robotics, but as the head of US Sales for Mazor while that deal was being hatched with MDT, also to provide guidance for both parties on executing the deal, partially modeled after the Mazor/MDT deal? Certainly a logical conclusion, when looking at the timelines not only for his Titan tenure but also for the entire to play out.
Differences that we know of are Mr. Martha's comments about the issues he found in retrospect with the Mazor deal - that they waited too long to acquire and have control of the product development, as they recalled systems and replaced them once MDT "fixed" those issues. That, coupled with his comments about wanting to acquire technologies before they are complete, and develop and grow those businesses as part of MDT... It doesn't take much of a leap to think they can't wait too much longer to snag Titan. And Mr. Zaring was involved in the architecture for the whole thing.
Message in reply to:
Or maybe Chad looked under the hood of Titan, liked what he saw, did his job, and left. You clowns have no idea what’s going on. The fact that you act with certainty is what is hilarious. To think you know what’s going on from your little surface level observations is toooo funny. I suppose you saw the Medtronic licensing agreement coming down the pipeline as well?
BK, I have been suggesting for a long time that everyone with any questions or concerns should write or call the company with their questions. By presenting those questions here instead of directly to the company, the answers include opinions and argument instead of just direct, factual answers. It creates an opportunity to continue to argue and spread more false information.
Of course, if they did get these factual answers from the company, their subsequent posts would probably either claim the company is lying, or point to history in which funding prevented the company from following through with scheduled activities - ignoring the fact that Titan now has funding for another complete year of these planned activities.
And as for the narrative of the Mazor deal meaning Titan would not continue to function under Medtronic, here's an interesting link:
https://www.calcalistech.com/ctech/articles/0,7340,L-3769370,00.html
Nine months after the acquisition was announced, Mazor leased a large additional space to continue expansion of their operations under the Mazor umbrella. BTW... a square meter is almost 11 sq ft so this was nearly 60,000 square feet of additional space. In case anyone wonders why Dr. Genova is planning for future development, the Mazor model still applies.
Message in reply to:
Rob,
I've answered many of those points, most of which were posted on or soon after you arrived in September.
...
I don't think your questions (to the wrong audience I might add) are directed to the source of the answers that which you seek.
...
I'm going to suggest to you, and the cadre of those that have a less-than-glossy view of this company to ask all of your questions to the IR department, or McNally. No one on this board will be able to respond to your accusations, answer your questions or address your issues. In what ever light you care to present them. Let us know how that works out.
timteo, keep in mind that any surgeon so highly competent as to be offered the opportunity to join anyone's SAB or similar panel will always be required to sign an NDA which is binding long after completion of services. A doctor who isn't skilled enough to ever be asked to join an SAB might not realize this.
Monk, I'm with you on this! In fact, any Big Pharma company who can afford a couple/few billion for ADMP probably already has their own compounding facilities or at least sufficient contracted capability to not need another facility. Maybe the sale of our compounding assets was a precursor to acquisition, which may have been in the works for the better part of the year. It takes a while to properly vet a multi-billion dollar deal which involves licensing deals in both directions, a new drug approval, ongoing clinical trials, etc. And it could explain the silence regarding financials, ZIMHI rollout plans, and everything else we don't know about. And as the landscape for COVID is changing almost daily - new drugs and vaxxes, new issues with drugs and vaxxes, new strains identified every week - it could be constant re-negotiation process until they can announce something.
Hopefully soon we will know just how savvy a negotiator Dr. Carlo really is!
Message in reply to:
All the more reason I think Roll is right about BO talks. Buyer will want to have their name on Tempol and prob doesn’t want the waters muddied. The stock not dropping below 1.03 kind of like a markers been placed here while something is being hashed out.
That's because their wildest dreams were to have a pill with better than Merck's 50% efficacy! Not really lofty aspirations, so they were likely to hit that target. But the hype! Wow, you'd think Geraldo Rivera was going to open up Al Capone's secret vault! Same thing here, tons of hype and insufficient substance to back it up.
What is the efficacy of Pfizer's new med on it's own, without the HIV med added in to make it work? In fact, what does Ritonavir do for COVID efficacy on its own??? For all we know Ritonavir is more effective by itself!
Message in reply to:
"Pfizer says effectiveness of COVID antiviral pill is 'beyond our wildest dreams'"
https://www.yahoo.com/news/pfizer-says-effectiveness-covid-antiviral-110635778.html
I don't trust PFE or any of these big pharma companies
Monk, as you know, some of us are also playing with Ocugen and their Covaxin candidate, which used the whole strand instead of the mRNA segment which only creates a variant-specific solution. From what I have been reading, deployment of Covaxin should handle the full spectrum of COVID variants, much like ADMP's Tempol will do for active infections of any strain. I have no need to own Pfizer, Moderna, etc. with their limited-scope solutions. I think when all the data comes out, only a few will show clear superiority and the current big names will be found out for whatever they are really doing behind the scenes. All IMO, but that's also where I'm putting my investment dollars - not in the Bigs that are due for a crash, but in the little players with honest, viable solutions to these real world COVID problems.
From where exactly does the market know about epipens and money coming in, if the company hasn't released financials?
Message in reply to:
It really doesn't matter what I think, it's about what the market thinks and right now they know about the epipens, Zimhi and money coming in and here we sit at 1.05. Now, tomorrow that could change based on whether Tempol is confirmed to be what some believe is the holy grail for COVID treatment.
And with Tollovir's decades of exceptional safety to back it up, it should be the clear winner. Oh, wait, never mind. That's Tempol which has decades of data showing safety in a market that's aiming to be dominated by meds with a laundry list of risky side effects. My bad.
Yes, I can. And so can you after you read Pages
15 thru 17 of Exhibit 99.2 Development and License Agreement.
Message in reply to:
Can you shed some more light on how the sub licensing works?
Dimitraki, thanks for the post and link.
My biggest take-aways from the article:
1) "bringing in $4.2 billion of revenue and $2.9 billion of gross profit so far this year." ISRG in 9 months pulled in $4.2B in revenue and $2.9B in profit. That means they made $2.9B profit off of $1.3B in costs! Around 225% profit above their relatively meager cost basis... No wonder their customers are upset! And that's $1.4B in revenue per quarter, so a little under $6B revenue for the year. More than half from instruments and accessories alone. Not too shabby, and proof that there is plenty of money in this market for competition.
2) "It could be as many as five years before J&J's Ottava actually hits the market in the U.S. or Europe after trials are conducted and regulatory review, a complex process with multiple hurdles that could spur further delays." JnJ announced a 2 year delay, but the article puts them at market approval in 5 years! 5 years from now before they can sell Ottava serial number 000000001. Enos is expected to be available for sale in 24 months or less. Just thought I'd mention that.
3) "In the context of a market that may be 5% or less penetrated ... taking the time now and getting it right makes sense." If ISRG's nearly $6B revenue represents less that 5% of the potential market, the opportunity is for more than $100B of market potential per year.
So with Medtronic just starting their FDA process hoping to be selling systems here in 2 years, and such a huge market opportunity remaining untapped... JnJ should be stepping up to the Titan plate with an offer. It opens the doors to that market place up to 3 or more 3 years sooner than their current schedule. And it's not that those first 3 years are necessarily going to generate gigantic revenues; it is a building process. So if JnJ puts Enos in the US market 3 years earlier than Ottava, they start building that customer base in robotics 3 years earlier and they would be collecting third year revenues from Enos before Ottava earns its first nickel. Besides the growing revenue stream, they would have sales, service, and support systems in place prior to the Ottava launch. This would be a score for JnJ on so many levels!
Competition can be good. Even better if two companies are competing to buy out my investment in Titan!
Message in reply to:
https://www.medtechdive.com/news/jj-ottava-delay-intuitive-surgical-medtronic-robotic-surgery/609090/
$1.03 = Games.
We were held in the $0.60s and 0.70s for most of April and May, then a jump over a dollar. We've been hovering around that dollar mark ever since then, and even with FDA approval of Zimhi, we are still pinned here. The real kicker is that we have about the same outstanding share count as TMDI but we have around 10X the daily trading volume as them, and with all that volume every day, we still can't seem to break free of the dollar territory. All Games.
The Strength will come, maybe with the financials being released and clearing the NASDAQ hurdle, or maybe with a Big saying "We need that!" But it will come in some form.
Didn't Computer Motion end up owning around a third of ISRG because of a patent infringement case? If I recall correctly (as happens occasionally) CM sued ISRG, the upshot was ISRG bought little tiny Computer Motion for... sorry, MERGED with them... with CM shareholders owning around a third of the combined company. So today's value for CM shareholders is now up around $40B because ISRG trampled on a handful of CM patents and got called on it.
I think the IP mattered in that situation as well.
Frankestin, thanks again as always for sharing Titan's ever-expanding approved IP portfolio. Earlier this week I reviewed their patent approvals since their June 30th tally shown in a presentation. Based on that count, this makes 100 approved patents! Almost worthy of a PR!
Just did a quick re-count, based on my post 131052 from 8/12. At that time, I used the TMDI June 30 presentation figure and added fro there:
82 per the presentation, June 30
July 6, 1 approval (83)
July 29, 3 approvals (86)
August 5, 2 approvals (88)
Aug 12, 1 more (89)
Aug 26, 1 more (90)
Aug 31, 1 more (91)
Sept 2, 1 more (92)
Sept 7, 2 more (94)
Sept 14, 1 more (95)
Sept 16, 1 more (96)
Sept 21, 1 more (97)
Oct 19, 1 more (98)
Today, Oct 26, 1 more = 99!
This data comes from your posts on each of the days called out above, and we all thank you BIGLY from the bottom of our hearts for continuing to provide this valuable info to all of us as each of these patents are approved!
Message in reply to:
I think 93 US and international patents issued
Frankestin, does this make 99 or 100 approved patents?
People should also be free to research and form their own opinions on things like uptake from inhalants vs. intramuscular injection, time lapsed for sufficient % of treatment to enter the bloodstream (especially in such a time-critical situation), and the dose size offered by ZIMHI vs. these numerous nasal offerings. I think ZIMHI will prove superior on all three counts, but again, people should do their own homework and form valid opinions based on real data.
I'd write more but one of my favorite old songs from Smokey Robinson just came on the radio! (I bet some of you can guess which song...)
Anybody can poke themselves with a needle by ignoring the instructions and/or being generally careless. That is true fir ZIMHI, COVID vaccines, and sewing, among numerous other activities which use needles.
The instructions very clearly state how to operate the device safely and how to deploy the safety sheath in a safe manner. I do not want to receive medical care from someone who is incapable of following these very clear and simple instructions.
Part of the FDA approval process and review and acceptance of safety criteria, and their approval of this product (and our Symjepi product which uses a very similar device) shows what the FDA's opinion is with regard to safety of this device.
Next, someone should complain to the FDA that the device is an eye hazard because it doesn't say "Do not push the device into your eyeball."
It does, however, say:
"'- Never put thumb, fingers, or hand over the exposed needle. Failure to follow these instructions may result in a
needlestick injury"
It also says:
"Right after the injection, using one hand with fingers behind the
needle, slide the safety guard over the needle."
And, similarly, as you noted below:
"'- Immediately after injection, using one hand with fingers behind the needle, slide the safety guard over the needle. Do not
use two hands to activate the safety guard.'"
Don't forget:
"Stress to patients the importance of familiarizing themselves with the device and its operation prior to experiencing an emergency situation."
If the user (medical professional or not) follows the simple instructions, the only needle contact is the intentional and necessary needle contact with the PATIENT ONLY.
I believe your "evidence" is a gross and blatant misinterpretation of the facts to try to besmirch the product, the company, and me. I again ask that others review all the information in this post, yours and mine, and judge for themselves.
Message in reply to:
Post 3501 " No needle contact by medical personnel." This is not true as per the FDA document provided. You asked for evidence and I give you the FDA.
Also, if this is to be used my non medical professionals so the concerns I have laid out are valid and backed by this document. This has been completely ignored.
Information below was pulled from link at bottom of post which is instructions on Zimhi.
'Risk of Accidental Needlestick Injury: After use, the ZIMHI needle is exposed until the safety guard is deployed. Stress to patients the importance of familiarizing themselves with the device and its operation prior to experiencing an emergency situation, and to immediately seek medical attention should a needlestick occur.'
'- Embed the needle completely before transferring the thumb to the syringe plunger.'
'- Immediately after injection, using one hand with fingers behind the needle, slide the safety guard over the needle. Do not
use two hands to activate the safety guard.'
'- Never put thumb, fingers, or hand over the exposed needle. Failure to follow these instructions may result in a
needlestick injury. If an accidental needlestick occurs, get medical help immediately [see Warnings and Precautions
(5.4)].'
'- Do NOT attempt to re-cap the needle with the needle cap once it has been removed [see Warnings and Precautions
(5.4)].'
https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212854s000lbl.pdf#:~:text=%285.3%29%20%E2%80%A2%20Risk%20of%20Accidental%20Needlestick%20Injury%3A%20After,seek%20medical%20attention%20should%20a%20needlestick%20occur.%20%285.4%29
Hey, guess what everyone??? In case you hadn't heard, a CNBC commentator said No Needle with ZIMHI! It's BIG NEWS, apparently!
Roll, does that say Vanguard has two funds which combined to buy over six million shares on 8/30? Just under the 5% threshold for SEC paperwork? They would hate to needles-ly do all that paperwork! So they stay just a little pinprick under the limit, huh?
I'm just taking a stab at this! I'm not always up to speed on corporate financials and stuff; I can be a bit poke-y trying to figure that stuff out.
(I'm not clowning around; it really looks to me like they bought 6 million shares!)
Geo, the reason I didn't put his #5 as an option is because I don't believe it is an option. Nobody can get into this market as a competitor without substantial resources. Titan has the tech and the product and the IP, but they will never have a marketing force powerful enough to make a serious impact here. Check their job listings - nothing remotely related to marketing. Deepak and Chris? Deepak is there for his M&A experience. Chris has a very limited LinkedIn profile; his Titan Medical profile says that he worked at Stereotasxis, ISRG, and four start-up companies but LinkedIn only shows Stereotaxis and ISRG. It would be nice of we could maybe see what he did at those start-ups, but without that possibly useful information, I can't assess his potential ability to bring an RAS system into the marketplace against such daunting competition as ISRG and MDT.
So no option #5 on my list, and that is a calculated omission.
Message in reply to:
HC, you party crasher you!
Anyone's point that medical professionals are all keenly aware of safe utilization of needles for administering drugs seems to get glossed over here. Think of the thousands of quickly-trained National Guardsmen who have been using open needles to inject COVID vaccines into arms all over the country. Anyone care to look into how many needle stick issues they have had despite very rudimentary training? Probably a few; I really don't know. But not such a big issue as to stop Joe's vax movement. Not even so bad as to require vaccines come in an injector device like ZIMHI.
Now of course ZIMHI has a needle, but it also comes with the sheath ("safety guard" per the instructions) which slides down from the body of the device. No needle contact by medical personnel. Click the Instructions for Use link on this page:
https://zimhi.com/
Very easy and pretty darned safe looking compared to over 200 million vaccines over the past year.
Everyone should look for themselves and draw your own conclusions if needle safety is an issue with ADMP's newly approved product.
It may be premature to declare "McNally is our hero" but many of us believe it will become a valid statement.
As for JnJ, that just further shows the difficulty in getting to the point that Titan is now at. JnJ can take a one quarter charge of $900M because of a 2 year delay. When a one year Hugo delay was announced (in late 2019? Early 2020?) that was further evidence.
For JnJ this 2 year delay puts them at least 3 years away from the marketing of their system. Great opportunity for MDT to push Hugo globally before a huge competitor like JnJ can dig in. But it also increases Titan's inherent value by virtue of their relative proximity to marketability. Meaning whoever wants to pony up a few billy can have a/another product offering sooner than JnJ's Ottava.
So, possibilities include...
1) JnJ could snag us, beat their Ottava to market and starts collecting revenue/foot in the door of the marketplace before MDT gets too far ahead.
2)MDT can snag us quickly, finish Enos to their liking and get a second product on the market before big competitor JnJ gets Ottava to market.
3) ISRG could snag us and keep both JnJ and MDT from building too much robotic strength for the next couple years.
4) Anyone else can jump in out of the blue (maybe Stryker?) and shortcut all the above.
SMirza, do you have a link to share?
Thanks in advance...
Message in reply to:
"Great to hear that Hugo received a CE mark. When will the FDA do the same? and the Titan Enos won't be far behind! Great team to join indeed!"
-John Lenihan ( Chief clinical officer)Mimic Technologies,
I'm Medtronic's website 2 days ago
Buyout Hint!
Thanks again Josey. And my apologies if you feel you are caught in any crossfire conversations.
My hometown provides an Overdose Kit in a zipper pouch for addicts to keep with them. In the event of an OD, they are most likely too incapacitated to administer to themselves but anyone nearby can follow the printed instructions to attempt to revive them. I do not know what form the meds are in those kits.
Given their existing Symjepi product, I would see no reason they shouldn't quickly apply a similar packaging solution to the ZIMHI product as well.
I'm glad you share our optimism for the usefulness of the newly approved product and for the future of our investments.
Message in reply to:
66, the more I read about ZIMHi overall, I truly believe they will develop an auto-injector, similar to an epipen.
This is designed for a layperson to use, in addition to prehospital(ems/fire/pd) and hospital staff.
The higher dose of ZIMHi is specifically created to combat the Fentanyl surge. As I’ve been out of the loop, so to speak, I’m guessing that Narcan nasal alone hasn’t been sufficient in competing with fentanyl, and thus the higher blood concentration of Narcan in ZIMHi will likely allow for improved patient resuscitation numbers.
Given the fentanyl epidemic, I would think this will end up being added to treatment algorithms nationwide.
Ignore the stock price, and manipulation. The science works, and the FDA just confirmed it. Ignore the noise.
Thank you Josey; I appreciate the response as well as the additional background in the mechanism such a medication uses to combat the OD scenario. I was unaware of the action of both the narcotic and the "remedy" on the binding sites. I may need to do a little more research, as SRC had suggested. I suspect it will only further validate my opinion of the value ZIMHI should have.
Message in reply to:
66, I’m not certain. I’ve been out of the prehospital arena since 2010, but within that timeframe I was a paramedic, I had almost always seen a single dose of Narcan work well. But that was mostly oxycodone and heroine ODs.
That said, my medic time was before the current epidemic street use of fentanyl and doping of other drugs with Remifentanyl. Those two drugs could perhaps create the situation you mention, as narcan is a Competitive Antagonist. Essentially Narcan (naloxone) competes for binding sites with opioids. An extra dose of opioids (or in this case, perhaps a stronger opioid) has a greater chance of overwhelming the Narcan.
As an aside, a non-competitive antagonist for Benzos (Valium, etc) is Romazicon. You could dump benzos in after, but they cannot bind.
This is exactly why I asked someone with real world experience for their opinion on the advantages of ZIMHI instead of asking someone with no experience in this matter to provide their "factual feedback" without having a basis for their "facts". But there a valuable takeaway here...
Josey, how important is that extra 2-3 minutes when attempting to save someone's life from an OD of Fentanyl? Do you think ZIMHI would have been advantageous as a first dose in those scenarios?
And apparently of equal importance, how dangerous do you (yes, only Josey again) as a trained professional feel it is to be using needles to administer life saving medications? Are there not possibly dozens of medications already administered by needle on an emergency basis for everything from stroke and diabetic shock to various cardiac emergencies? Or are EMT's inherently afraid of using needles to save a patient's life?
Thank you again for any valuable feedback you might provide.
Message in reply to:
I watch Cops so I am somewhat of an expert (JK!) in these matters as they constantly apply narcan via nasal spray to 'victims'. If the product isn't effective in the first 2-3 minutes they can give additional doses up to a certain limit I believe.
Is there enough of difference between the 4 and 5 and the way in which it is applied (nasal vs injection) to justify incorporating the risk and training to us a needle out in the field, forget about the red tape in city, state and Fed government. Maybe the market is currently providing us with that answer.
This is factual feedback and not feedback to fit to a certain narrative b/c I am desperate to be right that it's all sunshine and rainbows. I do not have blinders when it comes to investing.
Maybe all our eggs are in one basket now...Tempol.
Josey, I have heard anecdotally that, particularly with Fentanyl and other modern street narcotics, some patients have an incomplete response to an initial dosing of Naloxone and therefore require a second dose for resuscitation/revival. I have also heard that there is some time interval required to make the assessment of whether or not a second dose is required for a particular patient, and that additional time can be rather critical in determining the outcome.
As an experienced medical professional, have you ever found this to be true in own experience? It seems the intent of the ZIMHI product is to allow for a substantial enough dosing that a second dose should not be required, but without risk of providing the patient with TOO much Naloxone. If your experience includes any instances of a second dosing being required, to me that would certainly help validate the entire reason for the ZIMHI product regardless of the means of administering it (nasal vs. injection).
I appreciate any honest feedback you can provide on this.
Message in reply to:
Needle safety guards are super easy to use, both in an OR or in the back of a moving ambulance. I’ve done both, extensively.
This was the standard for IV catheters for a long time. Then they moved to a
Push-button system- which is safer, but I personally like less as you can accidentally trigger the needle retraction with slightly too much pressure.
So ADMP could easily move to a push button system.
However, I will admit, intranasal admin is drastically easier prehospital.
The stock market didn't ignore it. A bunch of folks jumped in blindly and gave Merck a quick 1-day boost. Then more folks started reading upon it, doing legitimate Due Diligence, and finding out more about the dangerous side of the drug. Mainstream media doesn't seem to focus much on the downsides and risks, so it takes a little more digging than just relying on what CNN or the All Biden Channel (ABC) will tell you.
Looking forward to when Tempol gets the Yahoo, CNN, and mainstream Red Carpet it deserves, instead of the Red Flag merely for being from a smaller company.
Message in reply to:
"This development may fully reopen the global economy — and the stock market has mostly ignored it "
https://www.yahoo.com/finance/m/45dae387-7481-36fc-8b1a-7ebe452b88a3/this-development-may-fully.html
Wow. Just Wow.
MDT bought the MIRA/Hugo technology from a division of the German Government. Not merely licensed it, they BOUGHT it, meaning the German government no longer had any rights to it.
The tech MDT has LICENSED from Titan is only LICENSED, and it is clearly stated that Titan retains the rights to all this shared technology including the right to sell themselves to a competitor who then also possesses the ability to compete against MDT with the same technology. Whereas the MIRA tech is now exclusively owned by MDT, the Titan tech is not. Big difference.
So... What's left? Do I need to point out that MDT did not buy out the "company" from which they bought the MIRA/Hugo tech? I mean, after all, it IS part of the government of Germany. The right hand side bar of the article says "The German Aerospace Center (DLR) is the national aeronautics and space research centre of the Federal Republic of Germany." But the deal must be proof that MDT won't buy Titan because they didn't buy the German government.